Stable insulin formulations
The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
1. A method for treating diabetes comprising administering an effective dose of a solution formulation, the solution formulation comprising
a physiologically tolerated buffer selected from the group consisting of 2-amino-2-hydroxymethyl-1,3-propanediol and arginine;
a monomeric insulin analog;
zinc;
a phenolic preservative; and
an isotonicity agent,
wherein the solution formulation is administered using a continuous infusion system.
2. The method of claim 1 , wherein the solution formulation is a stable formulation.
3. The method of claim 1 , wherein the buffer is 2-amino-2-hydroxymethyl-1,3-propanediol.
4. The method of claim 1 , wherein the monomeric insulin analog is Asp B28 -human insulin.
5. The method of claim 1 , wherein the monomeric insulin analog is Lys B28 Pro B29 -human insulin.
6. The method of claim 1 , wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22° C.
7. The method of claim 1 , wherein the concentration of the monomeric insulin analog is between about 1.2 mg/mL and about 50 mg/mL.
8. The method of claim 7 , wherein the concentration of the monomeric insulin analog is between about 3.0 mg/mL and about 35 mg/mL.
9. The method of claim 4 , wherein the concentration of Asp B28 -human insulin is between about 1.2 mg/mL and about 50 mg/mL.
10. The method of claim 9 , wherein the concentration of Asp B28 -human insulin is between about 3.0 mg/mL and about 35 mg/mL.
11. The method of claim 5 , wherein the concentration of Lys B28 Pro B29 -human insulin is between about 1.2 mg/mL and about 50 mg/mL.
12. The method of claim 11 , wherein the concentration of Lys B28 Pro B29 -human insulin is between about 3.0 mg/mL and about 35 mg/mL.
13. A method for treating hyperglycemia comprising administering an effective dose of a solution formulation, the solution formulation comprising
a physiologically tolerated buffer selected from the group consisting of 2-amino-2-hydroxymethyl-1,3-propanediol and arginine;
a monomeric insulin analog;
zinc;
a phenolic preservative; and
an isotonicity agent,
wherein the solution formulation is administered using a continuous infusion system.
14. The method of claim 13 , wherein the solution formulation is a stable formulation.
15. The method of claim 13 , wherein the buffer is 2-amino-2-hydroxymethyl-1,3-propanediol.
16. The method of claim 13 , wherein the monomeric insulin analog is Asp B28 -human insulin.
17. The method of claim 13 , wherein the monomeric insulin analog is Lys B28 Pro B29 -human insulin.
18. The method of claim 13 , wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22° C.
19. The method of claim 13 , wherein the concentration of the monomeric insulin analog is between about 1.2 mg/mL and about 50 mg/mL.
20. The method of claim 19 , wherein the concentration of the monomeric insulin analog is between about 3.0 mg/mL and about 35 mg/mL.
21. The method of claim 16 , wherein the concentration of Asp B28 -human insulin is between about 1.2 mg/mL and about 50 mg/mL.
22. The method of claim 21 , wherein the concentration of Asp B28 -human insulin is between about 3.0 mg/mL and about 35 mg/mL.
23. The method of claim 17 , wherein the concentration of Lys B28 Pro B29 -human insulin is between about 1.2 mg/mL and about 50 mg/mL.
24. The method of claim 23 , wherein the concentration of Lys B28 Pro B29 -human insulin is between about 3.0 mg/mL, and about 35 mg/mL.